Mounjaro Shows Promise in Reducing Alcohol Consumption and Relapse
Tirzepatide, the active ingredient in the medication Mounjaro, has demonstrated a significant reduction in both alcohol intake and relapse-like behaviors in preclinical studies involving rats and mice, suggesting a potential avenue for new treatments targeting alcohol addiction.1
Building on Previous Research with Semaglutide
Researchers at the University of Gothenburg have previously shown that semaglutide, found in Ozempic and Wegovy, similarly suppresses alcohol intake in rats. This latest research expands on those findings by investigating tirzepatide and Mounjaro specifically.1
Dual-Action Mechanism of Tirzepatide
Tirzepatide is unique as the first drug with a dual action on receptors for the satiety hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).4 Approved by the U.S. Food and Drug Administration (USFDA) in May 2022 for the treatment of type 2 diabetes, it has quickly turn into a widely prescribed medication, largely due to its effects on weight management.4 Its established clinical employ and safety profile could facilitate future studies exploring its potential in treating alcohol addiction.1
Key Findings from Animal Studies
Experiments conducted on rats and mice revealed that voluntary alcohol intake was more than halved in animals administered tirzepatide. The drug effectively prevented relapse drinking; animals did not increase their alcohol consumption after a period of abstinence and instead exhibited a decrease compared to their baseline intake.1
“We saw clear and strong reductions in both long-term alcohol drinking, excessive drinking and relapse drinking in both sexes. What makes the study particularly interesting is that we also gained a new insight into how this type of drug can affect the brain’s reward system,” says Christian Edvardsson, a PhD student in pharmacology at the Sahlgrenska Academy at the University of Gothenburg.1
Impact on the Brain’s Reward System
The study demonstrated that tirzepatide dampened alcohol’s effect on dopamine, a crucial signaling molecule in the brain’s reward system responsible for the pleasurable sensations associated with alcohol consumption.1
This effect appears to be mediated, at least in part, through the lateral septum, a brain region linked to motivation, reward, and relapse in both animals and humans. These findings offer a potential explanation for previous observations that similar drugs can reduce alcohol intake and cravings.1
Changes in Histone-Related Proteins
Researchers observed changes in histone-related proteins within the lateral septum. These proteins influence gene expression and have previously been linked to drug use and addiction.1 While the study doesn’t establish a direct causal link between these changes and reduced alcohol consumption, the results suggest they may be part of the biological mechanisms affected by tirzepatide.1
Future Directions and Potential Treatment Options
The research, a collaboration between Gothenburg University and the Medical University of South Carolina, combined behavioral tests, measurements of brain signaling substances, and molecular analyses.1
“This is not yet a new treatment for alcohol addiction. But the results strengthen the picture that drugs that affect these systems in the brain can be relevant to further study in order to find new treatment options,” states Elisabet Jerlhag, professor of pharmacology at the Sahlgrenska Academy at the University of Gothenburg.1
Understanding Alcohol Addiction
Alcohol addiction is a chronic brain disease characterized by alterations in the reward system, leading to persistent cravings even when an individual desires to stop drinking, and a high risk of relapse.1 This disease impacts both physical and mental health, increasing the risk of liver disease, cardiovascular disease, depression, and anxiety, and carries significant social and economic burdens.1
Current treatments for alcohol addiction have varying effectiveness, highlighting the need for more options with diverse mechanisms of action to enable personalized treatment approaches.1
Scientific Article: Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents, eBioMedicine.1
Disclaimer: This article provides information for educational purposes only and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to your health or treatment.